Aurinia Pharmaceuticals Inc. (AUPH)

Market Cap	776.59M
Revenue (ttm)	191.41M
Net Income (ttm)	-62.56M
Shares Out	143.02M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	37.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	555,809
Open	5.50
Previous Close	5.49
Day's Range	5.42 - 5.55
52-Week Range	4.71 - 12.43
Beta	1.42
Analysts	Strong Buy
Price Target	10.33 (+90.24%)
Earnings Date	Aug 1, 2024

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 1999
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: AUPH

Financial Performance

In 2023, AUPH's revenue was $175.51 million, an increase of 30.95% compared to the previous year's $134.03 million. Losses were -$78.02 million, -27.88% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is $10.33, which is an increase of 90.24% from the latest price.

Price Target

$10.33

(90.24% upside)

Analyst Consensus: Strong Buy